JAK1 and diffuse large B-cell lymphoma: In DLBCL, mutations affecting the JAK/STAT pathway have been detected as relapse-enriched genetic alterations, including JAK1, STAT6, SOCS1 and downstream target PIM1 [34,44,48,51,53].